First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
Epistemonikos ID: 001444ec0c6f6c5283ccb9fde6b17ea75b0ac1b7
First added on: Feb 01, 2025